U.S. markets closed

Omeros Corporation (OMER)

NasdaqGM - NasdaqGM Precio en tiempo real. Divisa en USD.
Añadir a la lista de seguimiento
3.4500+0.0300 (+0.88%)
Al cierre: 04:00PM EDT
3.4500 0.00 (0.00%)
Fuera de horario: 04:02PM EDT

Omeros Corporation

The Omeros Building
201 Elliott Avenue West
Seattle, WA 98119
United States
206 676 5000
https://www.omeros.com

Sector(es)Healthcare
IndustriaBiotechnology
Empleados a tiempo completo196

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Dr. Gregory A. Demopulos M.D.Co-Founder, Chairman, CEO & President1.79MN/D1959
Mr. Michael A. JacobsenChief Accounting Officer, VP of Finance & Treasurer518.6kN/D1958
Mr. Peter B. Cancelmo J.D.VP, General Counsel & Corporate Secretary503.24kN/D1979
Dr. Pamela Pierce Palmer M.D., Ph.D.Co-FounderN/DN/D1963
Dr. George A. Gaitanaris M.D., Ph.D.Chief Scientific Officer & VP of ScienceN/DN/D1957
Mr. Peter W. WilliamsVice President of Human ResourcesN/DN/D1968
Dr. Catherine A. Melfi Ph.D.Chief Regulatory Officer & VP of Regulatory Affairs and Quality SystemsN/DN/D1959
Ms. Nadia DacVP & Chief Commercial OfficerN/DN/D1970
Dr. Andreas Grauer M.D.Chief Medical OfficerN/DN/D1961
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that is in phase Ib clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders; and OMS405 that is in phase II clinical trials for opioid and nicotine addiction. In addition, the company develops MASP-2-small-molecule inhibitors for the treatment of aHUS, HSCT-TMA, and age-related macular degeneration; GPR174 inhibitors and chimeric antigen receptor T-Cell and adoptive T-Cell therapies for various cancers; and G protein-coupled receptors for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Gestión corporativa

La calificación ISS Governance QuickScore de Omeros Corporation a partir del 1 de marzo de 2024 es 7. Las puntuaciones principales son Auditoría: 8; Junta: 9; Derechos del accionista: 5; Compensación: 8.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.